This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Generex, Part II

Stocks in this article: CTIC GNBT NVS SPPI VNDA

BOSTON ( TheStreet) -- The more I dig into Generex Biotechnology (GNBT) and its insulin spray for diabetics, the more preposterous the story becomes.

I wasn't planning to spend a lot of time writing about this penny stock after last week's Biotech Stock Mailbag, but then the angry emails and comments came flooding in. On Tuesday, Generex issued a press release demanding I retract my "false and misleading" article. At the same time, I received a punchy letter from Generex CEO Anna Gluskin, via her attorney, in which she called me "malicious."


The Hostile React-o-Meter went to 11!

For a veteran reporter and columnist like myself who enjoys nothing more than exposing the modern day snake oil salesmen of the biotech age, Generex's all-bluster-no-bite protestations are a huge red flag.

As I burrow into Generex, it becomes apparent almost immediately that the company is using science and the quest to develop an alternative insulin delivery method not to actually help diabetics but as a ruse to perpetuate a 15 year-long stock promotion scheme. In the process, investors are getting fleeced while Generex management earns millions of dollars in compensation. Gluskin was paid $1.15 million in total compensation for the company's 2008 fiscal year.

I spoke with Gluskin briefly on Wednesday to ask her about Generex and Oral-lyn but she didn't want to comment without her lawyer on the phone. I agreed but they never called me back.

In a comment posted to last week's Mailbag, RJS9787 wrote, "Interesting take on Generex, Adam. Your two premises are completely false. First there have been numerous peer reviews for Oral-lyn dating back to the early part of this decade... In 2010, the two main independent researchers studying Oral-lyn, Dr. P. Raskin and Dr. P. Pozzilli, published the latest update for Oral-lyn's clinical development and this appeared in the peer-reviewed journal Diabetes, Obesity and Metabolism. All of the studies concluded by showing zero serious adverse effects attributed to Oral-lyn and that buccal spray insulin is non inferior, and often superior, to regular injectable insulin."

The February 2010 review article on Oral-lyn authored by Raskin and Pozzilli titled "Review of Clinical Trials: Update on Oral Insulin Spray Formulation" is helpful, but not in the way that RJS contends. Far from vindicating Oral-lyn, the article actually demonstrates quite clearly the lack of any credible clinical data to support the insulin spray's efficacy or safety.

1 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs